Clinical trial
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of…
NCT00408967 · EMD Serono, Industry · Withdrawn
Key facts
| NCT number | NCT00408967 |
|---|---|
| Title | Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. |
| Official title | An Open-label Phase II Study of Two Dose Levels of EMD 273066 Administered With Low-dose Cyclophosphamide Following Objective Response to Second-line Chemotherapy in Women With Recurrent Ovarian Carcinoma |
| Lead sponsor | EMD Serono, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Tucotuzumab celmoleukin (EMD 273066) |
| Enrollment | 0 |
| Start date | Dec 31, 2006 |
| Primary completion | May 31, 2008 |
| Completion | May 31, 2008 |
| First posted | Dec 8, 2006 |
| Last update posted | Aug 18, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: